SG10201601747XA - Anti-LRP5 Antibodies And Methods Of Use - Google Patents

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Microbiology (AREA)
Mycology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SG10201601747XA2012-01-182013-01-18Anti-LRP5 Antibodies And Methods Of UseSG10201601747XA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201261588100P	2012-01-18	2012-01-18

Publications (1)

Publication Number	Publication Date
SG10201601747XAtrue SG10201601747XA (en)	2016-04-28

Family

ID=47604271

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201601747XASG10201601747XA (en)	2012-01-18	2013-01-18	Anti-LRP5 Antibodies And Methods Of Use
SG11201404198TASG11201404198TA (en)	2012-01-18	2013-01-18	Anti-lrp5 antibodies and methods of use

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG11201404198TASG11201404198TA (en)	2012-01-18	2013-01-18	Anti-lrp5 antibodies and methods of use

Country Status (24)

Country	Link
US (4)	US9200072B2 (en)
EP (1)	EP2804629A1 (en)
JP (1)	JP6242813B2 (en)
KR (1)	KR20140116490A (en)
CN (1)	CN104066449B (en)
AR (1)	AR089752A1 (en)
AU (1)	AU2013209707A1 (en)
BR (1)	BR112014017518A2 (en)
CA (1)	CA2862422A1 (en)
CL (1)	CL2014001888A1 (en)
CO (1)	CO7000747A2 (en)
CR (1)	CR20140382A (en)
EA (1)	EA028202B1 (en)
IL (1)	IL233317A0 (en)
IN (1)	IN2014DN05885A (en)
MA (1)	MA35898B1 (en)
MX (1)	MX2014008157A (en)
NZ (1)	NZ626520A (en)
PE (1)	PE20141561A1 (en)
PH (1)	PH12014501605A1 (en)
SG (2)	SG10201601747XA (en)
TW (1)	TW201335187A (en)
WO (1)	WO2013109819A1 (en)
ZA (1)	ZA201404675B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5859307B2 (en)*	2008-09-10	2016-02-10	ジェネンテック，インコーポレイテッド	Methods for inhibiting ocular neovascularization
JP5861469B2 (en)*	2012-01-23	2016-02-16	日本電気硝子株式会社	Glass tube clean cutting device and clean cutting method
CN106488775A (en)	2014-07-11	2017-03-08	基因泰克公司	NOTCH approach suppresses
CA2959045A1 (en)	2014-09-12	2016-03-17	The University Of Washington	Wnt signaling agonist molecules
JP6933379B2 (en)*	2015-09-24	2021-09-08	ザユニバーシティオブノースカロライナアットチャペルヒル	Methods and compositions for reducing metastasis
CN106367517A (en)*	2016-09-28	2017-02-01	湖北工业大学	Low-density lipoprotein receptor-related protein 5 (LRP5) gene mutation detection reagents and application thereof
EP3618851A4 (en)*	2017-05-05	2020-04-15	Retinal Solutions LLC	Norrin induced expression of genes and use thereof to treat disease
WO2018220080A1 (en)	2017-05-31	2018-12-06	Boehringer Ingelheim International Gmbh	Polypeptides antagonizing wnt signaling in tumor cells
CA3085785A1 (en)*	2017-12-19	2019-06-27	Surrozen, Inc.	Anti-lrp5/6 antibodies and methods of use
CA3085596A1 (en)	2017-12-19	2019-06-27	Surrozen, Inc.	Anti-frizzled antibodies and methods of use
WO2019126398A1 (en)*	2017-12-19	2019-06-27	Surrozen, Inc.	Wnt surrogate molecules and uses thereof
EP3731864A1 (en)*	2017-12-29	2020-11-04	F. Hoffmann-La Roche SA	Anti-vegf antibodies and methods of use
JP2022544308A (en)*	2019-08-14	2022-10-17	モッドマブセラピューティクスインコーポレイテッド	Antibodies that bind to LRP5 protein and methods of use
CN115956089A (en)*	2020-05-04	2023-04-11	加利福尼亚大学董事会	Inhibitory anti-ENPP 1 antibodies
CN111909935B (en)*	2020-07-17	2022-11-15	武汉纽福斯生物科技有限公司	Expression vector of recombinant human frizzled protein receptor 4 (FZD 4) and application thereof
KR102536092B1 (en)*	2020-09-29	2023-05-24	조선대학교산학협력단	Pharmaceutical composition for the prevention or treatment of ischemic heart disease containing an inhibitor of LRP5 expression or activity
US20250270332A1 (en)	2020-12-18	2025-08-28	Antlera Therapeutics Inc.	Tetravalent FZD and WNT Co-Receptor Binding Antibody Molecules and Uses Thereof
WO2023250402A2 (en)*	2022-06-22	2023-12-28	Antlera Therapeutics Inc.	Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof
CN118599000A (en)*	2024-05-11	2024-09-06	中山大学附属第三医院	Application of LRP5 as a targeting molecule in the treatment of diabetic nephropathy

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4737456A (en)	1985-05-09	1988-04-12	Syntex (U.S.A.) Inc.	Reducing interference in ligand-receptor binding assays
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
US5606040A (en)	1987-10-30	1997-02-25	American Cyanamid Company	Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en)	1987-10-30	1998-06-23	American Cyanamid Company	Process for preparing targeted forms of methyltrithio antitumor agents
FI903489A7 (en)	1988-11-11	1990-07-10	Medical Res Council	Ligands containing one moiety, receptors containing these ligands, methods for their preparation and uses of the ligands and receptors
DE3920358A1 (en)	1989-06-22	1991-01-17	Behringwerke Ag	BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
CA2026147C (en)	1989-10-25	2006-02-07	Ravi J. Chari	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en)	1989-10-27	1999-09-28	The Scripps Research Institute	Transgenic plants expressing assembled secretory antibodies
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (en)	1990-12-03	1998-05-16	Genentech Inc	ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
US6407213B1 (en)	1991-06-14	2002-06-18	Genentech, Inc.	Method for making humanized antibodies
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
EP0604580A1 (en)	1991-09-19	1994-07-06	Genentech, Inc.	EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (en)	1991-10-07	1994-05-27	Oncologix Inc	Combination and method of use of anti-erbB-2 monoclonal antibodies
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
EP0625200B1 (en)	1992-02-06	2005-05-11	Chiron Corporation	Biosynthetic binding protein for cancer marker
EP0752248B1 (en)	1992-11-13	2000-09-27	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635483A (en)	1992-12-03	1997-06-03	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en)	1993-01-26	1998-07-14	Arizona Board Of Regents	Elucidation and synthesis of selected pentapeptides
JPH08511420A (en)	1993-06-16	1996-12-03	セルテック・セラピューテイクス・リミテッド	Body
US5773001A (en)	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en)	1994-11-03	1998-08-04	Genentech, Inc.	Process for bacterial production of polypeptides
US5840523A (en)	1995-03-01	1998-11-24	Genetech, Inc.	Methods and compositions for secretion of heterologous polypeptides
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US5714586A (en)	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en)	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
WO1998058964A1 (en)	1997-06-24	1998-12-30	Genentech, Inc.	Methods and compositions for galactosylated glycoproteins
US6040498A (en)	1998-08-11	2000-03-21	North Caroline State University	Genetically engineered duckweed
DE69840412D1 (en)	1997-10-31	2009-02-12	Genentech Inc	METHODS AND COMPOSITIONS CONTAINING GLYCOPROTEIN GLYCOR FORMS
US6610833B1 (en)	1997-11-24	2003-08-26	The Institute For Human Genetics And Biochemistry	Monoclonal human natural antibodies
DK1034298T3 (en)	1997-12-05	2012-01-30	Scripps Research Inst	Humanization of murine antibody
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
ES2292236T3 (en)	1998-04-02	2008-03-01	Genentech, Inc.	VARIATIONS OF ANTIBODIES AND THEIR FRAGMENTS.
WO1999054342A1 (en)	1998-04-20	1999-10-28	Pablo Umana	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
HUP0104865A3 (en)	1999-01-15	2004-07-28	Genentech Inc	Polypeptide variants with altered effector function
EP3031917A1 (en)	1999-04-09	2016-06-15	Kyowa Hakko Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
KR100797667B1 (en)	1999-10-04	2008-01-23	메디카고 인코포레이티드	How to regulate transcription of foreign genes
US7125978B1 (en)	1999-10-04	2006-10-24	Medicago Inc.	Promoter for regulating expression of foreign genes
EP1229125A4 (en)	1999-10-19	2005-06-01	Kyowa Hakko Kogyo Kk	PROCESS FOR PRODUCING A POLYPEPTIDE
JP2003516755A (en)	1999-12-15	2003-05-20	ジェネンテック・インコーポレーテッド	Shotgun scanning, a combined method for mapping functional protein epitopes
NZ518764A (en)	1999-12-29	2004-02-27	Immunogen Inc	Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
KR20020093029A (en)	2000-04-11	2002-12-12	제넨테크, 인크.	Multivalent Antibodies And Uses Therefor
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
EA013563B1 (en)	2000-10-06	2010-06-30	Киова Хакко Кирин Ко., Лтд.	A transgenic non-human animal, producing antibodies with modified sugar chains, a process for producing antibodies composition and a medicament comprising the antibodies
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
ES2405944T3 (en)	2000-11-30	2013-06-04	Medarex, Inc.	Nucleic acids encoding reorganized human immunoglobulin sequences from transgenic transchromosomal micezadas
NZ592087A (en)	2001-08-03	2012-11-30	Roche Glycart Ag	Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
PL213948B1 (en)	2001-10-25	2013-05-31	Genentech Inc	Glycoprotein compositions
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
CA2481920A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Antibody composition-containing medicament
AU2003236015A1 (en)	2002-04-09	2003-10-20	Kyowa Hakko Kirin Co., Ltd.	Process for producing antibody composition
EP1502603A4 (en)	2002-04-09	2006-12-13	Kyowa Hakko Kogyo Kk	MEDICAMENT CONTAINING ANTIBODY COMPOSITION APPROPRIATE TO PATIENT SUFFERING FROM POLYMORPHISM FC gammma RIIIA
PL373256A1 (en)	2002-04-09	2005-08-22	Kyowa Hakko Kogyo Co, Ltd.	Cells with modified genome
JPWO2003085119A1 (en)	2002-04-09	2005-08-11	協和醗酵工業株式会社	Method for enhancing binding activity of antibody composition to Fcγ receptor IIIa
ES2362419T3 (en)	2002-04-09	2011-07-05	Kyowa Hakko Kirin Co., Ltd.	CELLS WITH DEPRESSION OR DELETION OF THE ACTIVITY OF THE PROTEIN THAT PARTICIPATES IN THE TRANSPORT OF GDP-FUCOSA.
CA2488441C (en)	2002-06-03	2015-01-27	Genentech, Inc.	Synthetic antibody phage libraries
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2301966A1 (en)	2002-12-16	2011-03-30	Genentech, Inc.	Immunoglobulin variants and uses thereof
EP1585767A2 (en)	2003-01-16	2005-10-19	Genentech, Inc.	Synthetic antibody phage libraries
US20060104968A1 (en)	2003-03-05	2006-05-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en)	2003-03-05	2011-01-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20080241884A1 (en)	2003-10-08	2008-10-02	Kenya Shitara	Fused Protein Composition
US20070134759A1 (en)	2003-10-09	2007-06-14	Harue Nishiya	Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
DE602004026470D1 (en)	2003-11-05	2010-05-20	Roche Glycart Ag	FC RECEPTOR AND EFFECTOR FUNCTION
EP3858387A1 (en)	2003-11-06	2021-08-04	Seagen Inc.	Monomethylvaline compounds capable of conjugation to ligands
JPWO2005053742A1 (en)	2003-12-04	2007-06-28	協和醗酵工業株式会社	Medicament containing antibody composition
CN1961003B (en)	2004-03-31	2013-03-27	健泰科生物技术公司	Humanized anti-TGF-beta antibodies
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
PL1737891T3 (en)	2004-04-13	2013-08-30	Hoffmann La Roche	Anti-p-selectin antibodies
TWI309240B (en)	2004-09-17	2009-05-01	Hoffmann La Roche	Anti-ox40l antibodies
WO2006034488A2 (en)	2004-09-23	2006-03-30	Genentech, Inc.	Cysteine engineered antibodies and conjugates
JO3000B1 (en)	2004-10-20	2016-09-05	Genentech Inc	Antibody Formulations.
ES2577292T3 (en)	2005-11-07	2016-07-14	Genentech, Inc.	Binding polypeptides with diversified VH / VL hypervariable sequences and consensus
US20070237764A1 (en)	2005-12-02	2007-10-11	Genentech, Inc.	Binding polypeptides with restricted diversity sequences
JP2009536527A (en)	2006-05-09	2009-10-15	ジェネンテック・インコーポレーテッド	Binding polypeptide with optimized scaffold
WO2008027236A2 (en)	2006-08-30	2008-03-06	Genentech, Inc.	Multispecific antibodies
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (en)	2007-05-25	2010-02-24	群康科技(深圳)有限公司	Liquid crystal display panel driving device and driving method thereof
US20090074668A1 (en)*	2007-09-14	2009-03-19	Farjo Rafal A	Vldlr-/- mouse models and related methods
PL2235064T3 (en)	2008-01-07	2016-06-30	Amgen Inc	Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JP5859307B2 (en)	2008-09-10	2016-02-10	ジェネンテック，インコーポレイテッド	Methods for inhibiting ocular neovascularization

2013
- 2013-01-18KRKR1020147022497Apatent/KR20140116490A/ennot_activeWithdrawn
- 2013-01-18ARARP130100154Apatent/AR089752A1/enunknown
- 2013-01-18CNCN201380006007.8Apatent/CN104066449B/ennot_activeExpired - Fee Related
- 2013-01-18SGSG10201601747XApatent/SG10201601747XA/enunknown
- 2013-01-18EAEA201491357Apatent/EA028202B1/ennot_activeIP Right Cessation
- 2013-01-18AUAU2013209707Apatent/AU2013209707A1/ennot_activeAbandoned
- 2013-01-18TWTW102102128Apatent/TW201335187A/enunknown
- 2013-01-18NZNZ626520Apatent/NZ626520A/ennot_activeIP Right Cessation
- 2013-01-18EPEP13701352.0Apatent/EP2804629A1/ennot_activeWithdrawn
- 2013-01-18MXMX2014008157Apatent/MX2014008157A/enunknown
- 2013-01-18ININ5885DEN2014patent/IN2014DN05885A/enunknown
- 2013-01-18BRBR112014017518Apatent/BR112014017518A2/ennot_activeIP Right Cessation
- 2013-01-18USUS13/744,766patent/US9200072B2/enactiveActive
- 2013-01-18SGSG11201404198TApatent/SG11201404198TA/enunknown
- 2013-01-18WOPCT/US2013/022045patent/WO2013109819A1/enactiveApplication Filing
- 2013-01-18PEPE2014001118Apatent/PE20141561A1/ennot_activeApplication Discontinuation
- 2013-01-18JPJP2014553427Apatent/JP6242813B2/ennot_activeExpired - Fee Related
- 2013-01-18CACA2862422Apatent/CA2862422A1/ennot_activeAbandoned
2014
- 2014-06-23ILIL233317Apatent/IL233317A0/enunknown
- 2014-06-25ZAZA2014/04675Apatent/ZA201404675B/enunknown
- 2014-07-09COCO14147904Apatent/CO7000747A2/enunknown
- 2014-07-11PHPH12014501605Apatent/PH12014501605A1/enunknown
- 2014-07-17CLCL2014001888Apatent/CL2014001888A1/enunknown
- 2014-08-06MAMA37268Apatent/MA35898B1/enunknown
- 2014-08-13CRCR20140382Apatent/CR20140382A/enunknown
2015
- 2015-10-09USUS14/879,702patent/US9522954B2/ennot_activeExpired - Fee Related
2016
- 2016-11-11USUS15/349,757patent/US10035854B2/enactiveActive
2018
- 2018-06-26USUS16/018,458patent/US20190010228A1/ennot_activeAbandoned

Also Published As

Publication number	Publication date
BR112014017518A8 (en)	2017-07-04
CO7000747A2 (en)	2014-07-21
MA35898B1 (en)	2014-12-01
US20170166636A1 (en)	2017-06-15
EP2804629A1 (en)	2014-11-26
CL2014001888A1 (en)	2014-10-03
NZ626520A (en)	2016-09-30
AU2013209707A1 (en)	2014-07-24
ZA201404675B (en)	2016-11-30
KR20140116490A (en)	2014-10-02
CA2862422A1 (en)	2013-07-25
AR089752A1 (en)	2014-09-17
EA201491357A1 (en)	2014-11-28
US9522954B2 (en)	2016-12-20
JP6242813B2 (en)	2017-12-06
PH12014501605A1 (en)	2014-10-08
SG11201404198TA (en)	2014-08-28
CN104066449A (en)	2014-09-24
PE20141561A1 (en)	2014-11-12
US20130183320A1 (en)	2013-07-18
JP2015511119A (en)	2015-04-16
MX2014008157A (en)	2014-10-06
CN104066449B (en)	2018-04-27
WO2013109819A1 (en)	2013-07-25
BR112014017518A2 (en)	2018-09-04
US20160185855A1 (en)	2016-06-30
US20190010228A1 (en)	2019-01-10
IN2014DN05885A (en)	2015-06-05
EA028202B1 (en)	2017-10-31
US9200072B2 (en)	2015-12-01
TW201335187A (en)	2013-09-01
IL233317A0 (en)	2014-08-31
US10035854B2 (en)	2018-07-31
HK1197187A1 (en)	2015-01-09
CR20140382A (en)	2014-10-07

Publication	Publication Date	Title
ZA201501858B (en)	2016-11-30	Anti-mcam antibodies and associated methods of use
IL263320A (en)	2018-12-31	Anti-hemagglutinin antibodies and methods of use
ZA201406967B (en)	2021-06-30	Anti sez6 antibodies and methods of use
IL238227A0 (en)	2015-06-30	Anti-c16orf54 antibodies and methods of use thereof
ZA201404675B (en)	2016-11-30	Anti-lrp5 antibodies and methods of use
ZA201603308B (en)	2019-11-27	Novel anti-claudin antibodies and methods of use
ZA201408236B (en)	2016-01-27	Anti-ly6e antibodies and immunoconjugates and methods of use
IL245946A0 (en)	2016-07-31	Novel anti-dpep3 antibodies and methods of use
ZA201405864B (en)	2015-11-25	Cd47 antibodies and methods of use thereof
PT2925782T (en)	2020-04-22	Anti-cd47 antibodies and methods of use thereof
ZA201403760B (en)	2017-09-27	Anti-cd98 antibodies and methods of use thereof
IL232055B (en)	2020-11-30	Anti-htra1 antibodies and methods of use
SI2869837T1 (en)	2016-12-30	Anti-theophylline antibodies and methods of use

Movatterモバイル変換

SG10201601747XA - Anti-LRP5 Antibodies And Methods Of Use - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (1)

Publications (1)

Family

ID=47604271

Family Applications (2)

Family Applications After (1)

Country Status (24)

Families Citing this family (20)

Family Cites Families (95)

Also Published As

Similar Documents